Cited 229 times in
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.